Drug Trial Radar · NCT06343311
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Jun 1, 2024
Primary completion
Jul 31, 2027
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- Estrella Immunopharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Eureka Therapeutics Inc.
- First posted
- Apr 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated lymphoma, primary and secondary central nervous system (CNS) lymphoma, and a wide range of high-grade B-cell lymphomas (HGBLs), as well as R/R large B-cell lymphoma (LBCL) patients ineligible for autologous transplant.
Conditions
- B-Cell Non-Hodgkin's Lymphoma (NHL)
- Lymphoma, Non-Hodgkins
- Lymphomas Non-Hodgkin's B-Cell
- Non-Hodgkin Lymphoma
- Non-Hodgkin's Lymphoma
- Large B-Cell Lymphoma
- Lymphoma, Non-Hodgkin's, Adult
- Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Lymphoma, Non-Hodgkin
- HIV Associated Lymphoma
- CNS Lymphoma
- High-grade B-cell Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
EB103Biological
EB103 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of EB103.Time frame: Up to 2 years (active assessment period); additional long-term follow-up (LTFU) up to 15 years
- To determine the Recommended Phase II Dose (RP2D) of EB103 (in Phase 1, Dose Escalation)Time frame: Time Frame: 16 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of California, Davis
Sacramento, California · Recruiting
University Hospitals Seidman Cancer Center
Cleveland, Ohio · Recruiting
Oregon Health and Sciences University
Portland, Oregon · Recruiting
Baylor Scott & White Research Institute, Texas Oncology
Dallas, Texas · Recruiting
Intermountain Health, Canyons Region, LDS Hospital
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.